CKD Pharm, Zafgen may resume clinical trials of obesity treatment
IndustryJan 25, 2016
A treatment for a rare obesity treatment, originally developed by South Korea’s Chong Kun Dang Pharmaceutical and licensed to Zafgen in 2009, is geared to fully resume clinical trials in the near future.Zafgen, a U.S. biopharmaceutical company, said last week that beloranib has shown proven effectiveness in reducing body weight in a final-stage clinical study which was temporarily halted by the U.S. Food and Drug Administration last year.The FDA took the decision after the company confirmed the